This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease


Kieburtz, Karl, Landwehrmeyer, G. B., HORIZON Investigators of the Huntington Study Group,, European Huntington's Disease Network,


JAMA Neurology, Volume: 70, No.: 1, Pages.: 25-33

Year of Publication



BACKGROUND Latrepirdine is an orally administered experimental small molecule that was initially developed as an antihistamine and subsequently was shown to stabilize mitochondrial membranes and function, which might be impaired in Huntington disease. OBJECTIVE To determine the effect of latrepirdine on cognition and global function in patients with mild to moderate Huntington disease. DESIGN Randomized, double-blind, placebo-controlled study. SETTING Sixty-four research centers in Australia, Europe, and North America. PATIENTS Four hundred three patients with mild to moderate Huntington disease and baseline cognitive impairment (Mini-Mental State Examination score, 10-26). INTERVENTION Latrepirdine (20 mg) vs matching placebo administered orally 3 times daily for 26 weeks. MAIN OUTCOME MEASURES The co-primary outcome measures were cognition as measured by the change in Mini-Mental State Examination score from baseline to week 26 and global function at week 26 as measured by the Clinician Interview-Based Impression of Change, plus carer interview, which ranges from 1 (marked improvement) to 7 (marked worsening). Secondary efficacy outcome measures included behavior, daily function, motor function, and safety. RESULTS The mean change in Mini-Mental State Examination score among participants randomized to latrepirdine (1.5-point improvement) did not differ significantly from that among participants randomized to placebo (1.3-point improvement) (P=.39). Similarly, the distribution of the Clinician Interview-Based Impression of Change, plus carer interview did not differ significantly among those randomized to latrepirdine compared with placebo (P=.84). No significant treatment effects were detected on the secondary efficacy outcome measures. The incidence of adverse events was similar between those randomized to latrepirdine (68.5%) and placebo (68.0%). CONCLUSION In patients with mild to moderate Huntington disease and cognitive impairment, treatment with latrepirdine for 6 months was safe and well tolerated but did not improve cognition or global function relative to placebo. TRIAL REGISTRATION Identifier: NCT00920946.;

Bibtex Citation

@article{2013, doi = {10.1001/2013.jamaneurol.382}, url = {}, year = 2013, month = {jan}, publisher = {American Medical Association ({AMA})}, volume = {70}, number = {1}, pages = {25}, title = {A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease}, journal = {{JAMA} Neurology} }


administration & dosage, adverse effects, australia, comorbidity, diagnosis, doubleblind method, drug therapy, epidemiology, female, humans, huntington disease, indoles, latrepirdine, male, middle aged, north america, placebos, psychiatric status rating scales, severity of illness index, treatment outcome

Countries of Study

Australia, Canada, Denmark, Germany, Italy, Netherlands, Poland, Sweden, Switzerland, UK, USA

Types of Dementia


Types of Study

Randomised Controlled Trial

Type of Outcomes

ADLs/IADLs, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions